The College of American Pathologists (CAP) has released its Q2 2026 Cancer Protocol updates, introducing significant revisions to breast cancer reporting and several other cancer protocols that laboratories use to standardize pathology diagnoses and support treatment decisions.
The quarterly update includes changes to eight cancer protocols, with the most extensive revisions affecting ductal carcinoma in situ (DCIS) and invasive breast cancer biopsy and resection protocols. The updates incorporate recommendations from the sixth edition of the World Health Organization (WHO) classification system and expand guidance for tumor characterization, grading, disease extent, and reporting of additional lesions.
For pathology laboratories, the changes may require updates to reporting templates, laboratory information systems, and pathologist workflows, particularly for organizations handling high volumes of breast cancer cases.
Breast pathology remains one of the most commonly reported cancer specialties, making these revisions especially significant for anatomic pathology laboratories. More detailed guidance may help improve reporting consistency while ensuring pathology findings align with evolving clinical and treatment recommendations.
New reporting requirements may affect laboratory operations
Beyond breast cancer, CAP also updated kidney cancer protocols, including refinements to tumor grading and simplified tumor size reporting. Head and neck protocols received revisions addressing HPV-associated oropharyngeal cancers and mucosal melanoma.
Several of the revised protocols carry accreditation implications.
CAP noted that some protocol changes include required elements tied to laboratory accreditation, and certain WHO-related updates may have separate implementation timelines. Laboratory professionals may need to review effective dates carefully to ensure compliance with accreditation requirements and avoid disruptions during inspections.
These updates highlight the increasingly dynamic nature of cancer reporting standards. As organizations such as WHO and the American Joint Committee on Cancer continue to revise disease classifications and staging criteria, pathology laboratories face growing pressure to rapidly incorporate new guidance into daily practice.
The quarterly protocol update process has become an important mechanism for maintaining standardized reporting across institutions. Consistent cancer reporting not only supports accurate diagnosis and staging, but also influences treatment selection, eligibility for targeted therapies, and long-term patient management.
Laboratory directors, pathology groups, and quality managers may want to review the CAP Summary of Revisions and assess whether local reporting templates, synoptic reports, and accreditation documentation require updates before implementation deadlines arrive.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.
